VWA5A polyclonal, anti-human, mouse, rat
€305.00
In stock
SKU
BS5627
Background:
VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.
Alternative Name:
von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, BCSC1, LOH11CR2A
Application Dilution: WB: 1:500~1:1000, IF: 1:200
Specificity: VWA5A polyclonal antibody detects endogenous levels of VWA5A protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 411-456 of Human VWA5A.
MW: ~ 86 kDa (isoform1), 46 kDa (isoform3)
Swis Prot.: O00534
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A.
Alternative Name:
von Willebrand factor A domain-containing protein 5A, Breast cancer suppressor candidate 1, BCSC-1, Loss of heterozygosity 11 chromosomal region 2 gene A protein, BCSC1, LOH11CR2A
Application Dilution: WB: 1:500~1:1000, IF: 1:200
Specificity: VWA5A polyclonal antibody detects endogenous levels of VWA5A protein.
Immunogen:
Synthetic peptide, corresponding to amino acids 411-456 of Human VWA5A.
MW: ~ 86 kDa (isoform1), 46 kDa (isoform3)
Swis Prot.: O00534
Purification & Purity:
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Format:
1mg/ml in PBS with 0.1% Sodium Azide, 50% Glycerol.
Storage:
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
For research use only, not for use in diagnostic procedure.
| Is Featured? | No |
|---|
Write Your Own Review